Frontier Development PLC — Transaction in Own Shares 2018

Sep 10, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1980A

Frontier Developments PLC

10 September 2018

10 September 2018

Frontier Developments plc

(the "Company")

EBT Share Purchase

The Company was notified on 7 September 2018, by the trustee of the Frontier Developments plc Employee Benefit Trust (the "EBT"), that the EBT had purchased 237,346 ordinary shares in the Company at an average price of £10.262204 per ordinary share on 7 September 2018. These ordinary shares are to be held in the EBT and are intended to be used to satisfy the exercise of share options by employees. The EBT is a discretionary trust for the benefit of the Company's employees, including the Directors of the Company.

Following this transaction, a total of 341,991 Ordinary Shares are held by the Company's employee benefit trust, representing 0.883 per cent of the Company's total voting rights.

Enquiries:

Frontier Developments	+44 (0)1223 394 300
David Braben, CEO Alex Bevis, CFO
Liberum - Nomad and Joint Broker	+44 (0)203 100 2000
Neil Patel /Cameron Duncan/William Hall
Finncap	+44 (0) 207 220 0500
Matt Goode/Giles Rolls
Tulchan Communications	+44 (0) 207 353 4200
James Macey White/Matt Low

About Frontier Developments plc 

Frontier Developments plc, listed on the AIM stock market (AIM: FDEV), is a leading independent creator of self-published video game franchises founded in 1994 by David Braben, co-author of the seminal Elite game. Based in Cambridge, Frontier uses its proprietary 'COBRA' game development technology to create innovative games, currently focusing on video game consoles and personal computers.

Frontier's LEI number: 213800B9LGPWUAZ9GX18.

www.frontier.co.uk                 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHLLFVIALIAIIT